193807-60-2

Daily oral administration of 200 mg/kg BPHA in mice results in potent inhibition of tumor-induced angiogenesis, primary tumor growth, and liver metastasis. The growth inhibition activity of BPHA is 48% and 45% in a B16-BL6 melanoma and F2 hemangio-endothelioma model, respectively^[1].